What are the advantages of brigatinib/brigatinib compared with other drugs?

Brigatinib (Brigatinib), as one of the second-generation ALK inhibitors, has gradually stood out in the field of targeted therapy for non-small cell lung cancer (NSCLC) in recent years and has become an important drug in the treatment options for ALK-positive patients. Compared with first-generation drugs such as crizotinib and even some third-generation ALK inhibitors of the same generation, brigatinib shows significant advantages in many key aspects. These advantages are not only reflected in the persistence of therapeutic effects, but also in the multiple clinical benefits brought about by the optimization of its molecular structure.

One of the major advantages of brigatinib is its ability to provide broader mutation coverage. Patients with ALK-positive non-small cell lung cancer often develop drug resistance after long-term use of crizotinib, and the mechanism is mostly caused by secondary ALK mutations or activation of the bypass pathway. As a second-generation drug, brigatinib is not only effective against primary ALK mutations, but can also overcome a variety of known ALK resistance mutations, including "gateway mutations" such as L1196M, giving it greater potential in the treatment of crizotinib resistance. This improvement in mutation barrier also allows brigatinib to maintain its anti-cancer effect longer during treatment and extend progression-free survival.

Brigatinib also has outstanding performance in controlling central nervous system (CNS) metastasis. Studies have shown that compared with crizotinib and some other ALK inhibitors, brigatinib has better blood-brain barrier permeability, which makes it more effective in preventing and controlling brain metastases. For patients with non-small cell lung cancer, central nervous system metastasis is a common and difficult clinical problem. This characteristic of brigatinib brings significant practical value to the clinic.

In terms of dose management and treatment tolerability, brigatinib also demonstrates a high degree of individual adaptability. The standard treatment strategy is usually the "introduction dose + maintenance dose" model, which starts with a lower dose to allow patients to gradually adapt to the drug and reduce the occurrence of early adverse reactions, and then enters the full-dose maintenance phase to maximize the drug effect. In clinical practice, patients generally tolerate it well, and adverse reactions are controllable, and most are reversible, making it easy to manage in the long term. Compared with the severe toxic and side effects caused by the high intensity of some third-generation ALK inhibitors, this feature of brigatinib is particularly important for patients who hope to use long-term medication to control their disease.

Another advantage that cannot be ignored is the rapid progress in the global launch and medical insurance coverage of brigatinib. The drug has been included in drug catalogs in many countries and has successfully entered the scope of medical insurance in the domestic market, greatly easing the financial burden on patients and improving its accessibility. This provides substantial treatment options for more patients with ALK-positive lung cancer, which is particularly critical in areas with relatively limited resources.

In summary, the reason why brigatinib stands out among manyALK inhibitors is mainly due to its strong coverage of drug-resistant mutations, good central nervous system control effect, high safety and tolerability, and good market accessibility. These characteristics make brigatinib not only an ideal alternative drug after resistance to crizotinib, but also gradually becoming the first choice in some initial treatment options.

Reference materials:https://www.alunbrig.com/